Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South
America.
The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog
alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more
patients will recover without severe permanent disability after acute treatment with
Recombinant Factor VIIa by reducing further intracerebral bleeding.